6541 — Tanvex Biopharma Income Statement
0.000.00%
Last trade - 00:00- TWD11.29bn
- TWD11.99bn
- TWD400.97m
Annual income statement for Tanvex Biopharma, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 5.41 | 22.4 | 61.4 | 34.7 | 401 |
| Cost of Revenue | |||||
| Gross Profit | 3.55 | -19.3 | 59.7 | 8.29 | -441 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 1,605 | 1,628 | 2,170 | 1,392 | 1,839 |
| Operating Profit | -1,599 | -1,606 | -2,109 | -1,357 | -1,438 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1,543 | -1,641 | -2,137 | -1,381 | -1,503 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1,543 | -1,641 | -2,137 | -1,382 | -1,500 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1,543 | -1,641 | -2,137 | -1,382 | -1,500 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -1,543 | -1,641 | -2,137 | -1,382 | -1,500 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -13.6 | -13.3 | -16.2 | -8.81 | -5.87 |
| Dividends per Share |